Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 3:45 p.m. PT in San Francisco.
加利福尼亞州南舊金山，2024年12月18日（GLOBE NEWSWIRE）——Septerna是一家處於臨床階段的生物技術公司，正在引領針對GPCR靶向藥物發現的新紀元，今天宣佈，Septerna的首席執行官及聯合創始人Jeffrey Finer萬.D.，Ph.D. 將於2025年1月14日（星期二）下午3:45在舊金山的第43屆年度J.P.摩根醫療保健會議上發表演講。
A live webcast will be available in the Investors & Media section of the company's website at and will be archived for 30 days following the presentation.
公司網站的投資者與媒體部分將提供直播網絡廣播，並將在演講後保存30天。
About Septerna
Septerna, Inc. is a clinical-stage biotechnology company pioneering a new era of GPCR drug discovery powered by its proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of its deep pipeline of oral small molecule product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Septerna was launched by preeminent drug discovery company builders and scientific leaders in the biochemistry, structural biology, and pharmacology of GPCRs. For more information, please visit .
關於Septerna
Septerna, Inc.是一家處於臨床階段的生物技術公司，正在利用其專有的原生複合物平台引領GPCR藥物發現的新紀元。其工業規模的平台旨在釋放GPCR療法的全部潛力，並導致了其深厚的口服小分子產品候選者管線的發現和開發，最初專注於治療三個治療領域的患者：內分泌學、免疫學和炎症以及代謝疾病。Septerna由在GPCR生物化學、結構生物學和藥理學領域的傑出藥物發現公司建設者和科學領袖組成。有關更多信息，請訪問 .
Investor Contact:
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com
投資者聯繫人：
雷妮·萊克
THRUST戰略通訊
renee@thrustsc.com
Media Contact:
Carly Scaduto
Carly Scaduto Consulting
Carly@carlyscadutoconsulting.com
媒體聯繫人：
卡莉·斯卡杜託
卡莉·斯卡杜諮詢公司
Carly@carlyscadutoconsulting.com
譯文內容由第三人軟體翻譯。